Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/30/2005CN1194688C Slow releasing microspheres of transcutaneous huperzine A and its derivative or salt for injection and its preparing process
03/30/2005CN1194687C Pharmaceutical formulations comprising amoxocyllin and clavulanate
03/30/2005CN1194686C Eye drops of fluconazole
03/30/2005CN1194685C Ophthalmic gel of marticarpine
03/30/2005CN1194684C Maltilate emulsion and preparation proless thereof
03/30/2005CN1194683C Silymarin behenic acid glyceride lipid nano particle oral solution dosage and its preparation method
03/30/2005CN1194682C Preparing process and usage of zine taurinate
03/30/2005CN1194681C Glycine betaine for antithrombosis
03/30/2005CN1194680C Anticancer nutritive Chinese medicine
03/30/2005CN1194679C External Tranilast lipid gel prepn and its prepn process
03/30/2005CN1194678C Tiopronin freeze-dried powder injection
03/30/2005CN1194677C Long-acting tretnoin intraocular slowly-releasing system
03/30/2005CN1194676C Use of amfetamine alcohol compounds as medicine for treating hepatitis B and preparation method thereof
03/30/2005CN1194675C Use of trans-3, 4, 5-trihydroxy-diphenyl in preparation of medicine for resisting hepatitis B virus
03/30/2005CN1194674C Novel diphenylethylene compounds
03/30/2005CN1194672C Transdermal therapeutic system with a highly effective neuroleptic agent
03/30/2005CN1194666C Preparation of Azthromycin solution and semi-solid
03/30/2005CN1194664C In-vivo gel preparation able to be dropped in eyes and its preparing process
03/29/2005US6872971 Scaffold-organized clusters and electronic made using such clusters
03/29/2005US6872853 Bioavailability; reacting sertratineamine with hydrogen chloride
03/29/2005US6872852 Polyamine analogues as cytotoxic agents
03/29/2005US6872851 Melatonergic receptors; antiinflammatory agents; anticancer agents
03/29/2005US6872840 Anticancer agents
03/29/2005US6872838 Derivatives of water insoluble drugs which exhibit good activity and water solubility
03/29/2005US6872837 Taxanes having a c10 Heterosubstituted acetate substituent
03/29/2005US6872834 Phenyl-substituted indoles and indazoles
03/29/2005US6872751 Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
03/29/2005US6872750 Modulating angiogenesis
03/29/2005US6872749 Administering to the cow salt of ester of methionine, an ester of methionine amide, and an ester of the hydroxy analogue of methionine
03/29/2005US6872747 Decalactones, method for making, and pharmaceuticals there from
03/29/2005US6872746 Isomeric fused pyrrolocarbazoles and isoindolones
03/29/2005US6872745 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
03/29/2005US6872744 Analgesics
03/29/2005US6872743 Antiinflammatory agents; sepsis shock; antiarthritic agents
03/29/2005US6872741 Sodium channel modulators
03/29/2005US6872740 4-(heteroarylethyl)-4,5-dihydro-1,3-thiazol-2-ylamine or salt, useful for treating an illness, which involves an abnormal production of nitric oxide (NO) by induction of an inducible NO-synthase
03/29/2005US6872739 Use of riluzole for the treatment of multiple sclerosis
03/29/2005US6872738 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
03/29/2005US6872737 Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis
03/29/2005US6872736 Non-aqueous emulsifiable concentrate formulation
03/29/2005US6872735 LFA-1 antagonist compounds
03/29/2005US6872734 Extended release of tiagabine hydrochloride ((R)-n-(4,4bis (3-methyl-2-thienyl)-3-butenyl)nipecotic acid hydrochloride)) which is effective as gamma-aminobutyric acid (GABA) uptake inhibitory compound
03/29/2005US6872733 Benzimidazolone compounds
03/29/2005US6872731 Imidazo-pyridine derivatives as ligands for GABA receptors
03/29/2005US6872730 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
03/29/2005US6872728 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
03/29/2005US6872725 Crystallized p38 kinase inhibitors for treatment of rheumatoid arthritis
03/29/2005US6872724 Active polymorphs of 4-(2-(5- cyano-thiazol-2-ylamino) pyridin-4-ylmethyl)-piperazine-1-active polymorphs of 4-(2 5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl)piperazine-1-carbo xylic acid methylamide which inhibit, regulate and/or modulate
03/29/2005US6872723 Stabilized difloxacin injectable solution
03/29/2005US6872722 Therapies for tissue damage resulting from ischemia
03/29/2005US6872721 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino-[1′,2′:1,6]pyrido[3,4b]-indole-1,4-dione
03/29/2005US6872720 Pyrazolo-triazine derivatives as ligands for gaba receptors
03/29/2005US6872719 Antiinflammatory agents; autoimmune disease
03/29/2005US6872714 Methods to modulate conditions mediated by the CXCR4 receptor
03/29/2005US6872713 Plant extracts
03/29/2005US6872712 Cyclic glycerophosphates and analogs thereof
03/29/2005US6872711 β-substituted β-aminoethyl phosphonate derivatives
03/29/2005US6872709 Using glycyrrhizin
03/29/2005US6872708 Local injection prescription
03/29/2005US6872707 Prevention, therapy of bacteria infections
03/29/2005US6872706 Hypoglycemic agents; antidiabetic agents; dietetics
03/29/2005US6872705 Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
03/29/2005US6872699 Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein
03/29/2005US6872542 Treatment or prophylaxis of diseases caused by pilus-forming bacteria
03/29/2005US6872415 Sugar-free pharmaceutical products
03/29/2005US6872407 Extended release formulations of erythromycin derivatives
03/29/2005US6872401 Prevention and/or treatment of photoaging of the skin; sunscreen agents
03/29/2005US6872400 Heat resistance; mixture with sequestering and neutralizing agent
03/29/2005US6872390 Local anesthetic methods and kits
03/29/2005US6872383 Administering macrolactone antibiotic KF-506
03/29/2005US6872382 Use of selective PDE IV inhibitors to treat dry eye disorders
03/29/2005US6872336 Spraying a solution wherein a poorly soluble drug is dissolved in a plasticizer, and an aqueous solution and/or water dispersion of a water-soluble polymer, from nozzle outlets simultaneously and separately.
03/29/2005US6872317 Comprises natural/regenerated fiber; waste treatment; pollution control
03/29/2005CA2425745C Expression of exogenous polynucleotide sequences in a vertebrate
03/29/2005CA2392879C A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
03/29/2005CA2335186C Pyrrolo[2,3-d]pyrimidine compounds
03/29/2005CA2301732C Therapeutic combinations
03/29/2005CA2280447C Pyrrolo¬1,2-a|pyrazine derivatives as 5ht1a ligands
03/29/2005CA2279897C Novel antioxidant mixture
03/29/2005CA2268870C Heterocyclic carboxamides
03/29/2005CA2261760C Sulfonamides and derivatives thereof that modulate the activity of endothelin
03/29/2005CA2257662C Quinoline derivatives as tachykinin nk3 receptor antagonists
03/29/2005CA2240541C Stabilisers for live vaccines
03/29/2005CA2217169C Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
03/29/2005CA2182582C Compositions containing micronized nebivolol
03/29/2005CA2176042C Alpha-aryl or heteroaryl-substituted amide ester acat inhibitors
03/29/2005CA2173505C Use of penciclovir for the treatment of post-herpetic neuralgia
03/29/2005CA2170772C Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
03/29/2005CA2100514C 17-spiromethylene steroids
03/29/2005CA2097444C Angiotensin ii antagonist imidazole derivatives, their preparation and their therapeutic use
03/29/2005CA2049287C Expression of exogenous polynucleotide sequences in a vertebrate
03/26/2005CA2442898A1 Fosinopril sodium tablet formulation
03/24/2005WO2005026783A2 Method for configuring air-core photonic-bandgap fibers free of surface modes
03/24/2005WO2005026741A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
03/24/2005WO2005026728A1 Screening method
03/24/2005WO2005026372A1 Polyethyleneglycol-modified lipid compounds and uses thereof
03/24/2005WO2005026357A1 Antisense oligonucleotides for prevention of metastasis formation of cancer cells
03/24/2005WO2005026324A2 Method and composition for enhancing in vitro embryo development by supplementing culture medium with prostaglandin or a prostaglandin analog
03/24/2005WO2005026318A2 Methods and compositions for producing antigenic responses
03/24/2005WO2005026253A2 Labile linkage for compound delivery to a cell
1 ... 4740 4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 4751 4752 4753 4754 4755 4756 4757 4758 4759 4760 ... 7860